Ian Y Lee, Simon Hanft, Michael Schulder, Kevin D Judy, Eric T Wong, J Bradley Elder, Linton T Evans, Mario Zuccarello, Julian Wu, Sonikpreet Aulakh, Vijay Agarwal, Rohan Ramakrishna, Brian J Gill, Alfredo Quiñones-Hinojosa, Cameron Brennan, Brad E Zacharia, Carlos Eduardo Silva Correia, Madhavi Diwanji, Gregory K Pennock, Charles Scott, Raul Perez-Olle, David W Andrews, John A Boockvar
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product of the Goldspire™ platform, is a first-in-class autologous immunotherapeutic product that combines personalized whole tumor-derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers, with the intent to induce a tumor-specific immune response in patients with ndGBM...
December 7, 2023: Future Oncology